The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells

Oncology Research

Volumn 21, Issue 3, 2013, Pages 155-164

  Ueno, Takunori ^a   Endo, Shinji ^a   Saito, Rie ^a   Hirose, Mitsuaki ^a   Hirai, Sachiko ^a   Suzuki, Hideo ^a   Yamato, Kenji ^a   Hyodo, Ichinosuke ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cancer therapy; Colorectal cancer; Death receptor 5 (DR5); Sirtuin 1 (SIRT1); Sirtuin 2 (SIRT2); Tenovin 6

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5; FIRTECAN; FLUOROURACIL; OXALIPLATIN; PROTEIN P53; SIRTUIN 1; SIRTUIN 2; TENOVIN 6; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; PLATINUM COMPLEX; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SIRTUIN; TENOVIN-6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GENE MUTATION; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CACO 2 CELL LINE; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HT 29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CACO-2 CELLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; RANDOM ALLOCATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIRTUIN 1; SIRTUIN 2; SIRTUINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904468203     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13854886566598     Document Type: Article

References (44)

1. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 408:307-310; 2000.
2. Sherr, C. J.; McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2:103-112; 2002.
3. Feki, A.; Irminger-Finger, I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52:103-116; 2004.
4. Inoue, T.; Hiratsuka, M.; Osaki, M.; Oshimura, M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6:1011-1018; 2007.
5. Guarente, L.; Franklin, H. Epstein Lecture: Sirtuins, aging, and medicine. N. Engl. J. Med. 364:2235-2244; 2011.
6. Donmez, G.; Guarente, L. Aging and disease: Connections to sirtuins. Aging Cell 9:285-290; 2010.
7. Carafa, V.; Nebbioso, A.; Altucci, L. Sirtuins and disease: The road ahead. Front. Pharmacol. 3:4; 2012.
8. Liu, T.; Liu, P. Y.; Marshall, G. M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702-1705; 2009.
9. Olmos, Y.; Brosens, J. J.; Lam, E. W. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist. Updat. 14:35-44; 2011.
10. Kruse, J. P.; Gu, W. Modes of p53 regulation. Cell 137:609- 622; 2009.
11. Kim, J. H.; Yoon, E. K.; Chung, H. J.; Park, S. Y.; Hong, K. M.; Lee, C. H.; Lee, Y. S.; Choi, K.; Yang, Y.; Kim, K.; Kim, I. H. p53 acetylation enhances Taxol-induced apoptosis in human cancer cells. Apoptosis 18:110-120; 2013.
12. Nosho, K.; Shima, K.; Irahara, N.; Kure, S.; Firestein, R.; Baba, Y.; Toyoda, S.; Chen, L.; Hazra, A.; Giovannucci, E. L.; Fuchs, C. S.; Ogino, S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod. Pathol. 22:922-932; 2009.
13. Cha, E. J.; Noh, S. J.; Kwon, K. S.; Kim, C. Y.; Park, B. H.; Park, H. S.; Lee, H.; Chung, M. J.; Kang, M. J.; Lee, D. G.; Moon, W. S.; Jang, K. Y. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 15:4453-4459; 2009.
14. Portmann, S.; Fahrner, R.; Lechleiter, A.; Keogh, A.; Overney, S.; Laemmle, A.; Mikami, K.; Montani, M.; Tschan, M. P.; Candinas, D.; Stroka, D. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol. Cancer Ther. 12:499-508; 2013.
15. Narayan, N.; Lee, I. H.; Borenstein, R.; Sun, J. H.; Wong, R.; Tong, G.; Fergusson, M. M.; Liu, J.; Rovira, I. I.; Cheng, H. L.; Wang, G. H.; Gucek, M.; et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 492:199-204; 2012.
16. Hammond, J. W.; Cai, D. W.; Verhey, K. J. Tubulin modifications and their cellular functions. Curr. Opin. Cell Biol. 20:71-76; 2008.
17. Brooks, C. L.; Gu, W. p53 Activation: A case against Sir. Cancer Cell 13:377-378; 2008.
18. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454-463; 2008.
19. Alcain, F. J.; Villalba, J. M. Sirtuin inhibitors. Expert Opin. Ther. Pat. 19:283-294; 2009.
20. McCarthy, A. R.; Pirrie, L.; Hollick, J. J.; Ronseaux, S.; Campbell, J.; Higgins, M.; Staples, O. D.; Tran, F.; Slawin, A. M.; Lain, S.; Westwood, N. J. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg. Med. Chem. 20:1779-1793; 2012.
21. Singh, T. R.; Shankar, S.; Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24:4609-4623; 2005.
22. Kim, Y. H.; Park, J. W.; Lee, J. Y.; Kwon, T. K. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25:1813-1820; 2004.
23. Nakata, S.; Yoshida, T.; Horinaka, M.; Shiraishi, T.; Wakada, M.; Sakai, T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271; 2004.
24. VanOosten, R. L.; Moore, J. M.; Karacay, B.; Griffith, T. S. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol. Ther. 4:1104-1112; 2005.
25. Earel, J. K., Jr.; VanOosten, R. L.; Griffith, T. S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66:499-507; 2006.
26. Fulda, S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp. Cell Res. 318:1208-1212; 2012.
27. Endo, S.; Yamato, K.; Hirai, S.; Moriwaki, T.; Fukuda, K.; Suzuki, H.; Abei, M.; Nakagawa, I.; Hyodo, I. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 102:605-613; 2011.
28. Yamato, K.; Yamada, T.; Kizaki, M.; Ui-Tei, K.; Natori, Y.; Fujino, M.; Nishihara, T.; Ikeda, Y.; Nasu, Y.; Saigo, K.; Yoshinouchi, M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 15:140-153; 2008.
29. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55; 1984.
30. Goloudina, A. R.; Demidov, O. N.; Garrido, C. Inhibition of HSP70: A challenging anti-cancer strategy. Cancer Lett. 325:117-124; 2012.
31. Guo, F.; Sigua, C.; Bali, P.; George, P.; Fiskus, W.; Scuto, A.; Annavarapu, S.; Mouttaki, A.; Sondarva, G.; Wei, S.; Wu, J.; Djeu, J.; et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105:1246-1255; 2005.
32. Musch, M. W.; Kaplan, B.; Chang, E. B. Role of increased basal expression of heat shock protein 72 in colonic epithelial c2BBE adenocarcinoma cells. Cell Growth Differ. 12:419-426; 2001.
33. Malago, J. J.; Koninkx, J. F.; Ovelgonne, H. H.; van Asten, F. J.; Swennenhuis, J. F.; van Dijk, J. E. Expression levels of heat shock proteins in enterocyte-like Caco-2 cells after exposure to Salmonella enteritidis. Cell Stress Chaperones 8:194-203; 2003.
34. Liu, G.; Su, L.; Hao, X.; Zhong, N.; Zhong, D.; Singhal, S.; Liu, X. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J. Cell. Mol. Med. 16:1618-1628; 2012.
35. Zou, W.; Liu, X.; Yue, P.; Zhou, Z.; Sporn, M. B.; Lotan, R.; Khuri, F. R.; Sun, S. Y. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl- 2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64:7570-7578; 2004.
36. Kong, R.; Jia, G.; Cheng, Z. X.; Wang, Y. W.; Mu, M.; Wang, S. J.; Pan, S. H.; Gao, Y.; Jiang, H. C.; Dong, D. L.; Sun, B. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated upregulation of death receptor 5. PLoS One 7:e37222; 2012.
37. Kim, M. J.; Hong, K. S.; Kim, H. B.; Lee, S. H.; Bae, J. H.; Kim, D. W.; Dao, T. T.; Oh, W. K.; Kang, C. D.; Kim, S. H. Ku70 acetylation and modulation of c-Myc/ATF4/ CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP. Int. J. Biochem. Cell Biol. 45:711-723; 2013.
38. Olszewski, U.; Hamilton, G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med. Chem. 10:293-301; 2010.
39. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 370:737-749; 2003.
40. Diyabalanage, H. V.; Granda, M. L.; Hooker, J. M. Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 329:1-8; 2013.
41. Butler, L. M.; Zhou, X.; Xu, W. S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99:11700-11705; 2002.
42. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; Kofler, R.; Smyth, M. J.; Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98:10833-10838; 2001.
43. Xu, L.; Qu, X.; Zhang, Y.; Hu, X.; Yang, X.; Hou, K.; Teng, Y.; Zhang, J.; Sada, K.; Liu, Y. Oxaliplatin enhances TRAILinduced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 583:943-948; 2009.
44. Kabra, N.; Li, Z. Y.; Chen, L. H.; Li, B. Z.; Zhang, X. H.; Wang, C. G.; Yeatman, T.; Coppola, D.; Chen, J. D. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 284:18210-18217; 2009.